Pelareorep Earns FDA Fast Track for Second-Line KRAS-Mutant Metastatic CRCByAndrea Eleazar, MHSFebruary 4th 2026
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRCByAndrea Eleazar, MHSFebruary 2nd 2026
mFOLFOX/Bevacizumab/Atezolizumab Improves PFS in dMMR/MSI-H Colorectal CancerBySabrina SeraniJanuary 12th 2026
Physical Activity: A Potential Pathway for Reducing Fatigue in Colorectal CancerByAndrea Eleazar, MHSJanuary 12th 2026